Leerink Partnrs Reduces Earnings Estimates for Beigene

Beigene, Ltd. (NASDAQ:ONC - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2026 earnings per share (EPS) estimates for Beigene in a research report issued on Thursday, February 27th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of $7.06 for the year, down from their prior forecast of $7.33. The consensus estimate for Beigene's current full-year earnings is ($5.82) per share.

A number of other equities research analysts have also issued reports on ONC. Macquarie upped their target price on Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a research note on Friday. Bank of America upgraded Beigene from a "neutral" rating to a "buy" rating and upped their price objective for the company from $207.00 to $320.00 in a research report on Monday.

Beigene Stock Down 9.7 %

Shares of ONC stock traded down $26.27 during trading hours on Monday, hitting $245.53. The company's stock had a trading volume of 1,291,907 shares, compared to its average volume of 443,150. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. Beigene has a twelve month low of $126.97 and a twelve month high of $287.88. The firm has a market capitalization of $24.03 billion, a PE ratio of -29.80, a P/E/G ratio of 7.73 and a beta of 0.63.

Beigene (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.55). The business had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%.

Insider Transactions at Beigene

In other news, Director Bros. Advisors Lp Baker sold 732,827 shares of the firm's stock in a transaction on Friday, February 28th. The stock was sold at an average price of $260.00, for a total transaction of $190,535,020.00. Following the sale, the director now owns 730,642 shares in the company, valued at $189,966,920. This trade represents a 50.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Chan Henry Lee sold 1,202 shares of the company's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $258.04, for a total value of $310,164.08. The disclosure for this sale can be found here. Insiders sold a total of 790,950 shares of company stock worth $204,616,547 over the last ninety days. 7.43% of the stock is currently owned by corporate insiders.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.